Cardinal Health (CAH) 10-Q 2 Feb 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2015	Jan. 27, 2016
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	cah
Entity Registrant Name	CARDINAL HEALTH INC
Entity Central Index Key	721,371
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		329,328,935

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue	$ 31,445	$ 25,537	$ 59,499	$ 49,607
Cost of products sold	29,836	24,083	56,311	46,813
Gross margin	1,609	1,454	3,188	2,794
Operating expenses:
Distribution, selling, general, and administrative expenses	922	815	1,764	1,590
Restructuring and employee severance	2	7	14	26
Amortization and other acquisition-related costs	114	60	219	112
Impairments and (gain)/loss on disposal of assets, net	(17)	18	(17)	18
Litigation (recoveries)/charges, net	(9)	44	(9)	72
Operating earnings	563	546	1,183	1,012
Other (income)/expense, net	(2)	(1)	6	(4)
Interest expense, net	45	36	90	70
Loss on extinguishment of debt	0	60	0	60
Earnings before income taxes	520	451	1,087	886
Provision for income taxes	194	162	377	331
Net Earnings	326	289	710	555
Net earnings attributable to non-controlling interests	0	0	(1)	0
Net earnings attributable to Cardinal Health, Inc.	$ 326	$ 289	$ 709	$ 555
Earnings per common share attributable to Cardinal Health, Inc.:
Net basic earnings per common share (in dollars per share)	$ 0.99	$ 0.87	$ 2.16	$ 1.66
Net diluted earnings per common share (in dollars per share)	$ 0.98	$ 0.86	$ 2.14	$ 1.65
Basic (in shares)	329	331	329	333
Diluted (in shares)	332	334	332	337
Cash dividends declared per common share	$ 0.3870	$ 0.3425	$ 0.7740	$ 0.6850

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net Earnings	$ 326	$ 289	$ 710	$ 555
Other comprehensive loss:
Foreign currency translation adjustments	(28)	(40)	(73)	(64)
Net unrealized loss on derivative instruments, net of tax	(1)	(9)	(1)	(9)
Total other comprehensive loss, net of tax	(29)	(49)	(74)	(73)
Total comprehensive income	297	240	636	482
Comprehensive income/(loss), net of tax attributable to noncontrolling interests	0	0	(1)	0
Total comprehensive income attributable to Cardinal Health, Inc.	$ 297	$ 240	$ 635	$ 482

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Current assets:
Cash and equivalents	$ 2,324	$ 4,616
Trade receivables, net	6,980	6,523
Inventories, net	11,007	9,211
Prepaid expenses and other	1,518	1,402
Total current assets	21,829	21,752
Property and equipment, net	1,651	1,506
Goodwill and other intangibles, net	9,113	6,018
Other assets	914	866
Total assets	33,507	30,142
Current liabilities:
Accounts payable	16,919	14,368
Current portion of long-term obligations and other short-term borrowings	354	281
Other accrued liabilities	1,606	2,594
Total current liabilities	18,879	17,243
Long-term obligations, less current portion	5,171	5,211
Deferred income taxes and other liabilities	2,609	1,432
Redeemable noncontrolling interests	120	0
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none	0	0
Common shares, without par value:
Authorized—755 million shares, Issued—364 million shares at December 31, 2015 and June 30, 2015	2,973	3,003
Retained earnings	5,972	5,521
Common shares in treasury, at cost: 34 million shares and 36 million shares at December 31, 2015 and June 30, 2015, respectively	(2,137)	(2,245)
Accumulated other comprehensive loss	(97)	(23)
Total Cardinal Health, Inc. shareholder's equity	6,711	6,256
Noncontrolling interests	17	0
Total shareholder's equity	6,728	6,256
Total liabilities, redeemable noncontrolling interests, and shareholders’ equity	$ 33,507	$ 30,142

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Jun. 30, 2015
Statement of Financial Position [Abstract]
Preferred shares, No Par Value
Preferred shares, Authorized	500,000	500,000
Preferred shares, Issued	0	0
Common shares, No Par Value
Common shares, Authorized	755,000,000	755,000,000
Common shares, Issued	364,000,000	364,000,000
Common shares in treasury	34,000,000	36,000,000

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net Earnings	$ 710,000,000	$ 555,000,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	306,000,000	220,000,000
Loss on extinguishment of debt	0	60,000,000
Gain on sale of other investments	0	(5,000,000)
Impairments and (gain)/loss on disposal of assets, net	17,000,000	(18,000,000)
Share-based compensation	56,000,000	53,000,000
Provision for bad debts	35,000,000	26,000,000
Change in fair value of contingent consideration obligation	(14,000,000)	0
Change in operating assets and liabilities, net of effects from acquisitions:
Increase in trade receivables	(393,000,000)	(291,000,000)
Increase in inventories	(1,565,000,000)	(1,137,000,000)
Increase in accounts payable	2,431,000,000	1,438,000,000
Other accrued liabilities and operating items, net	(172,000,000)	113,000,000
Net cash provided by operating activities	1,411,000,000	1,014,000,000
Cash flows from investing activities:
Acquisition of subsidiaries, net of cash acquired	(3,284,000,000)	(86,000,000)
Additions to property and equipment	(175,000,000)	(83,000,000)
Purchase of available-for-sale securities and other investments	(88,000,000)	(107,000,000)
Proceeds from sale of available-for-sale securities and other investments	57,000,000	107,000,000
Proceeds from maturities of available-for-sale securities	19,000,000	16,000,000
Proceeds from divestitures and disposal of held for sale assets	0	53,000,000
Net cash used in investing activities	(3,471,000,000)	(100,000,000)
Cash flows from financing activities:
Payment of contingent consideration obligation	(23,000,000)	0
Net change in short-term borrowings	39,000,000	(18,000,000)
Reduction of long-term obligations	(4,000,000)	(1,220,000,000)
Proceeds from long-term obligations, net of issuance costs	0	1,182,000,000
Net proceeds/(tax withholdings) from share-based compensation	(7,000,000)	35,000,000
Tax proceeds from share-based compensation	32,000,000	42,000,000
Dividends on common shares	(259,000,000)	(233,000,000)
Purchase of treasury shares	0	(686,000,000)
Net cash used in financing activities	(222,000,000)	(898,000,000)
Effect of exchange rate changes on cash and equivalents	(10,000,000)	0
Net increase/(decrease) in cash and equivalents	(2,292,000,000)	16,000,000
Cash and equivalents at beginning of period	4,616,000,000	2,865,000,000
Cash and equivalents at end of period	$ 2,324,000,000	$ 2,881,000,000

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2015 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the effective date of the acquisition or up to the date of disposal, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include all of the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In addition, operating results presented for this fiscal 2016 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2016 . These condensed consolidated financial statements are unaudited and are presented pursuant to the rules and regulations of the SEC. Accordingly, the condensed consolidated financial statements included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (the "2015 Form 10-K"). In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. Inventories A substantial portion of our inventories are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within these distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation. Interim LIFO calculations are based on our estimates of expected year-end inventory levels and costs, as the actual valuation of inventory under the LIFO method is computed at the end of the fiscal year based on the inventory levels and costs at that time. Based upon the year-to-date balance and expectations for the remainder of the fiscal year, we recorded a LIFO charge of $39 million for the three months ended December 31, 2015 , which is included in cost of products sold in the condensed consolidated financial statements. Recent Financial Accounting Standards In January 2016, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance intended to improve the recognition and measurement of financial instruments as part of a larger simplification initiative. The amended guidance primarily changes the accounting for equity method investments, financial liabilities under the fair value option, the method for assessing the realizability of deferred tax assets related to available-for-sale securities, and the presentation and disclosure requirements for financial instruments. This classification and measurement guidance will be effective for us in the first quarter of fiscal 2019, with early adoption permitted. We are currently evaluating the impact of the adoption on our consolidated financial statements. In November 2015, the FASB issued amended accounting guidance that simplifies the accounting for income taxes. Under this amended guidance, deferred tax assets and liabilities must be classified as noncurrent on the balance sheet instead of separating deferred tax items into current and noncurrent amounts. We adopted this guidance on a prospective basis in the second quarter of fiscal 2016. Upon adoption of this guidance, current deferred tax assets of $20 million and current deferred tax liabilities of $1.1 billion in our December 31, 2015 condensed consolidated balance sheet were reclassified as noncurrent. In accordance with the adoption of this guidance, balances were not retrospectively adjusted. The adoption of this guidance had no impact on our condensed consolidated statements of earnings, comprehensive income or cash flows. In September 2015, the FASB issued amended accounting guidance that eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments on a retrospective basis. Under this amended guidance, the acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment. We adopted this guidance in the second quarter of fiscal 2016. The adoption of this guidance did not materially impact our condensed consolidated financial statements. In May 2014, the FASB issued amended accounting guidance related to revenue recognition. This guidance is based on the principle that revenue is recognized in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB deferred the effective date for one year beyond the originally specified effective date. This amendment will be effective for us in the first quarter of fiscal 2019. We are continuing to evaluate the options for adoption and the impact on our consolidated financial statements. In April 2014, the FASB issued amended accounting guidance related to the reporting of discontinued operations and disclosures of disposals of components of an entity. The amended guidance changes the thresholds for disposals to qualify as discontinued operations and requires additional disclosures. We adopted this guidance in the first quarter of fiscal 2016. The adoption of this guidance did not impact our condensed consolidated financial statements.

Acquisitions

Acquisitions	6 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisitions	Acquisitions During the six months ended December 31, 2015 , we completed several acquisitions, the most significant of which are described in more detail below. The pro forma results of operations and the results of operations for acquired businesses since the acquisition dates have not been separately disclosed because the effects were not significant compared to the condensed consolidated financial statements, individually or in the aggregate. Cordis On October 2, 2015 , we acquired the Cordis business ("Cordis") from Ethicon, Inc., a wholly-owned subsidiary of Johnson & Johnson, for $1.9 billion using cash on hand and proceeds from our debt offering in June 2015. The acquisition of Cordis, a global manufacturer and distributor of interventional cardiology devices and endovascular solutions with operations in more than 50 countries, expands our Medical segment's portfolio of self-manufactured products and its geographic scope. We closed the Cordis acquisition in 20 principal countries on October 2, 2015, and acquired the rights to the net economic benefit from the entire Cordis business in the other countries at that time. For the remaining non-principal countries, we will acquire legal ownership in the next 24 months. The results for the entire Cordis business in all countries are included in the condensed consolidated financial statements as of and for the six months ended December 31, 2015. Transaction and integration costs associated with the acquisition of Cordis were $20 million and $41 million during the three and six months ended December 31, 2015 , respectively, and are included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings. naviHealth On August 26, 2015 , we acquired a 71 percent ownership interest in naviHealth Group Holdings, L.P. ("naviHealth") for $238 million , net of cash acquired of $53 million . We funded the acquisition with cash on hand. The acquisition of naviHealth, a leader in post-acute care management solutions, expands our ability to serve health plans, health systems, and providers. We consolidate the results of naviHealth in our condensed consolidated financial statements and report its consolidated results in our Medical segment. The terms of the agreement provide us with the option to acquire the remaining 29 percent noncontrolling interests at any time after the two-year anniversary of the closing. The third-party noncontrolling interests holders also hold an option, which allows them to sell their noncontrolling interests to us at any time after the two-year anniversary of the closing. Refer to Note 10 for further information on the redeemable noncontrolling interests. Harvard Drug On July 2, 2015 , we completed the acquisition of The Harvard Drug Group ("Harvard Drug") for $1.1 billion using cash on hand and proceeds from our debt offering in June 2015. The acquisition of Harvard Drug, a distributor of generic pharmaceuticals, over-the-counter healthcare and related products to retail, institutional and alternate care customers, enhances our Pharmaceutical segment's generic pharmaceutical distribution and related services businesses. Harvard Drug also manufactures and repackages generic pharmaceuticals and over-the-counter healthcare products. Fair Value of Assets Acquired and Liabilities Assumed The allocation of the purchase price for the acquisitions of Cordis, naviHealth, and Harvard Drug are not yet finalized and are subject to adjustment as we complete the valuation analysis for these acquisitions. The purchase prices are also subject to adjustment based on working capital requirements as set forth in the acquisition agreements. The valuation of identifiable intangible assets utilizes significant unobservable inputs and thus represents a Level 3 nonrecurring fair value measurement. The estimated fair value of the identifiable intangible assets was determined using an income-based approach, which includes market participant expectations of the cash flows that an asset could generate over its remaining useful life, discounted back to present value using an appropriate rate of return. The discount rates used to arrive at the present value of the identifiable intangible assets ranged from 12 percent to 14 percent , and reflect the internal rate of return and uncertainty in the cash flow projections. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition dates for Cordis, naviHealth, and Harvard Drug: (in millions) Cordis naviHealth Harvard Drug Identifiable intangible assets: Customer relationships (1) $ 230 $ 38 $ 470 Trade names (2) 130 16 130 Developed technology (3) 400 61 — In-process research and development (4) 55 — — Total identifiable intangible assets acquired 815 115 600 Cash and equivalents — 53 46 Trade receivables — 38 67 Inventories 213 — 49 Prepaid expenses and other 4 14 12 Property and equipment 98 5 16 Other assets 10 1 1 Accounts payable (81 ) (2 ) (48 ) Other accrued liabilities (11 ) (95 ) (39 ) Deferred income taxes and other liabilities (7 ) (42 ) (104 ) Redeemable noncontrolling interests — (119 ) — Total identifiable net assets/(liabilities) acquired 1,041 (32 ) 600 Goodwill 832 323 551 Total net assets acquired $ 1,873 $ 291 $ 1,151 (1) The weighted-average useful lives of customer relationships range from 4 to 13 years. (2) The weighted-average useful lives of trade names range from 10 to 17 years. (3) The weighted-average useful life of developed technology is 10 years. (4) Acquired in-process research and development ("IPR&D") intangible assets have an indefinite-life.

Restructuring and Employee Seve

Restructuring and Employee Severance	6 Months Ended
	Dec. 31, 2015
Restructuring Charges [Abstract]
Restructuring and Employee Severance	Restructuring and Employee Severance The following tables summarize restructuring and employee severance costs: Three Months Ended December 31 (in millions) 2015 2014 Employee-related costs (1) $ — $ 5 Facility exit and other costs (2) 2 2 Total restructuring and employee severance $ 2 $ 7 Six Months Ended December 31 (in millions) 2015 2014 Employee-related costs (1) $ 6 $ 21 Facility exit and other costs (2) 8 5 Total restructuring and employee severance $ 14 $ 26 (1) Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. (2) Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees, and costs associated with restructuring our delivery of information technology infrastructure services. The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2015 $ 22 $ — $ 22 Additions 7 2 9 Payments and other adjustments (13 ) — (13 ) Balance at December 31, 2015 $ 16 $ 2 $ 18

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical Total Balance at June 30, 2015 $ 2,199 $ 2,871 $ 5,070 Goodwill acquired, net of purchase price adjustments 578 1,178 1,756 Foreign currency translation adjustments and other (13 ) (14 ) (27 ) Balance at December 31, 2015 $ 2,764 $ 4,035 $ 6,799 The increase in the Pharmaceutical segment goodwill is primarily due to the Harvard Drug acquisition. Goodwill recognized in connection with this acquisition primarily represents the expected benefits from synergies of integrating this business, the existing workforce of the acquired entity, and expected growth from new customers. The increase in the Medical segment goodwill is primarily due to the Cordis and naviHealth acquisitions. Goodwill recognized in connection with the Cordis acquisition primarily represents the expected benefits from synergies of integrating the business, the existing workforce of the acquired entity, expected growth from new customers, and the expected growth from existing technology. Goodwill recognized in connection with the naviHealth acquisition primarily represents the existing workforce of the acquired entity, expected growth from new customers, new service offerings, and the expected growth from existing technology. See Note 2 for further discussion of these acquisitions. Other Intangible Assets The following tables summarize other intangible assets by class at: December 31, 2015 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 69 $ — $ 69 N/A Total indefinite-life intangibles 69 — 69 N/A Definite-life intangibles: Customer relationships 1,826 620 1,206 10 Trademarks, trade names, and patents 512 112 400 15 Developed technology and other 793 154 639 10 Total definite-life intangibles 3,131 886 2,245 11 Total other intangible assets $ 3,200 $ 886 $ 2,314 N/A June 30, 2015 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: Trademarks and other $ 14 $ — $ 14 Total indefinite-life intangibles 14 — 14 Definite-life intangibles: Customer relationships 1,103 501 602 Trademarks, trade names, and patents 237 91 146 Developed technology and other 320 134 186 Total definite-life intangibles 1,660 726 934 Total other intangible assets $ 1,674 $ 726 $ 948 Total amortization of intangible assets was $101 million and $47 million for the three months ended December 31, 2015 and 2014 , respectively, and $168 million and $92 million for the six months ended December 31, 2015 and 2014 , respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2016 through 2020 is as follows: $189 million , $368 million , $308 million , $255 million , and $228 million .

Available-for-Sale Securities

Available-for-Sale Securities	6 Months Ended
	Dec. 31, 2015
Available-for-sale Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Available-for-Sale Securities We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. We held the following investments in marketable securities at fair value at: (in millions) December 31, 2015 June 30, 2015 Current available-for-sale securities: Commercial paper $ 2 $ 4 Treasury bills 2 12 International bonds — 2 Corporate bonds 53 34 U.S. agency bonds 1 5 Asset-backed securities 28 8 International equity securities 2 — U.S. agency mortgage-backed securities 16 26 Total current available-for-sale securities 104 91 Long-term available-for-sale securities: International bonds 1 — Corporate bonds 29 33 U.S. agency bonds 31 18 Asset-backed securities 20 41 U.S. agency mortgage-backed securities 13 10 Total long-term available-for-sale securities 94 102 Total available-for-sale securities $ 198 $ 193 Gross unrealized gains and losses were immaterial at December 31, 2015 and June 30, 2015 . During the three and six months ended December 31, 2015 and 2014 , gross realized gains and losses were immaterial and we did not recognize any other-than-temporary impairments. At December 31, 2015 , the weighted-average effective maturity of our current and long-term investments was approximately 6 months and 14 months , respectively.

Income Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Fluctuations in our provision for income taxes as a percentage of pretax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. During the three months ended December 31, 2015 and 2014 , the effective tax rate was 37.3 percent and 36.0 percent , respectively. During the six months ended December 31, 2015 and 2014 , the effective tax rate was 34.7 percent and 37.4 percent , respectively. The effective tax rate during the six months ended December 31, 2015 was impacted by net favorable discrete items of $28 million . At December 31, 2015 and June 30, 2015 , we had $530 million and $542 million of unrecognized tax benefits, respectively. The December 31, 2015 and June 30, 2015 balances include $348 million and $357 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. At December 31, 2015 and June 30, 2015 , we had $154 million and $169 million , respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is a net decrease of zero to $190 million , exclusive of penalties and interest. We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2006 through the current fiscal year. We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $222 million and $219 million at December 31, 2015 , and June 30, 2015 , respectively, and is included in other assets in the condensed consolidated balance sheets.

Commitments, Contingent Liabili

Commitments, Contingent Liabilities and Litigation	6 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingent Liabilities and Litigation	Commitments, Contingent Liabilities and Litigation Commitments Generic Sourcing Venture With CVS Health Corporation In July 2014 , we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health Corporation (“CVS Health”) with an initial term of 10 years . Both companies have contributed sourcing and supply chain expertise to the 50/50 venture and have committed to source generic pharmaceuticals through arrangements negotiated by the venture. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of both companies. We are required to pay 39 quarterly payments of $25.6 million to CVS Health which commenced in October 2014 . Due to the achievement of a milestone, the quarterly payment to CVS Health increased by $10 million beginning in the first quarter of fiscal 2016. In addition, if an additional milestone is achieved, the quarterly payment will increase in fiscal 2017 by a further $10 million resulting in a maximum quarterly payment of $45.6 million if all milestones are met. Legal Proceedings We become involved from time to time in disputes, litigation, and regulatory matters incidental to our business. We may be named from time to time in qui tam actions, which are initiated by private third parties purporting to act on behalf of federal or state governments, that allege that false claims have been submitted or have been caused to be submitted for payment by the government. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own on behalf of the government. From time to time, we receive subpoenas or requests for information from various government agencies relating to our business or to the business of a customer, supplier, or other industry participant. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims, or the commencement of legal proceedings, against us. In addition, we may suspect that products we manufacture, market or distribute do not meet product specifications, published standards, or regulatory requirements. In such circumstances, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, and action by regulators. We accrue for contingencies related to disputes, litigation, and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. With respect to the matters described below, we are unable to estimate a range of reasonably possible loss for matters for which there is no accrual, or additional loss for matters for which we have recorded an accrual, since damages or fines have not been specified or the proceedings are at stages where significant uncertainty exists as to legal or factual issues and as to whether such matters will proceed to trial. We do not believe, based on currently available information, that the outcomes of these matters will have a material adverse effect on our financial position, results of operations, or cash flows, though the outcome of one or more of these matters could be material to our results of operations for a particular period. We recognize income from the favorable outcome of litigation when we receive the associated cash or assets. We recognize estimated loss contingencies for litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings. DEA Investigation and Related Matters In February 2012, the U.S. Drug Enforcement Administration (the "DEA") issued an order to show cause and immediate suspension of our Lakeland, Florida distribution center's registration to distribute controlled substances, asserting that we failed to maintain required controls against the diversion of controlled substances. In May 2012, we entered into a settlement agreement with the DEA that resolved the administrative aspects of the DEA's action but did not resolve potential liability for civil fines in Florida or elsewhere for the conduct covered by the settlement agreement. In that regard, we are continuing to discuss a settlement with the U.S. Department of Justice. Our total accrual for this matter at December 31, 2015 and June 30, 2015 was $44 million and $41 million , respectively, which is included in other accrued liabilities in the condensed consolidated balance sheets. State of West Virginia vs. Cardinal Health, Inc. Since June 2012, the West Virginia Attorney General has filed complaints against a number of pharmaceutical wholesale distributors, including us and Harvard Drug. The complaints, which were filed in the Circuit Court of Boone County, West Virginia, allege, among other things, that the distributors failed to maintain effective controls to guard against diversion of controlled substances in West Virginia, failed to report suspicious orders of controlled substances in accordance with the West Virginia Uniform Controlled Substances Act, and were negligent in distributing controlled substances to pharmacies that serve individuals who abuse controlled substances. The complaints seek, among other things, injunctive and other equitable relief and monetary damages. We are vigorously defending ourselves in this matter. Antitrust Litigation Proceeds We received and recognized income resulting from settlements of class action antitrust claims in which we were a class member of $13 million during both the three and six months ended December 31, 2015 .

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2015
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: December 31, 2015 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents (1) $ 554 $ — $ — $ 554 Forward contracts (2) — 5 — 5 Available-for-sale securities (3) — 198 — 198 Other investments (4) 115 — — 115 Liabilities: Contingent Consideration (5) — — (23 ) (23 ) June 30, 2015 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents (1) $ 1,809 $ — $ — $ 1,809 Forward contracts (2) — 5 — 5 Available-for-sale securities (3) — 193 — 193 Other investments (4) 111 — — 111 Liabilities: Contingent Consideration (5) — — (53 ) (53 ) (1) Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities. (2) The fair value of interest rate swaps, foreign currency contracts, and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets. (3) We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves, and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities. (4) The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (5) Contingent consideration represents the obligations incurred in connection with acquisitions. We do not deem the fair value of the contingent consideration obligations under any single acquisition to be significant. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or from achieving certain milestones. The fair value measurement is based on significant inputs unobservable in the market and thus represents a Level 3 measurement. Failure to meet current expectations of progress could increase the probability of not achieving the targets within the measurement periods and result in a reduction in the fair value of the contingent consideration obligation. The following table presents a reconciliation of those liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3): (in millions) Contingent Consideration Obligation Balance at June 30, 2015 $ 53 Additions from acquisitions 7 Changes in fair value of contingent consideration (1) (14 ) Payment of contingent consideration (23 ) Balance at December 31, 2015 $ 23 (1) Amount is included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.

Financial Instruments

Financial Instruments	6 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. Our derivative and hedging programs are consistent with those described in the 2015 Form 10-K. The amount of ineffectiveness associated with these derivative instruments was immaterial for the three and six months ended December 31, 2015 and 2014 . During the three months ended December 31, 2015 and 2014 , we entered into pay-floating interest rate swaps with total notional amounts of $300 million and $450 million , respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in other assets in the condensed consolidated balance sheets. During the three months ended September 30, 2014, we entered into forward interest rate swaps with a total notional amount of $50 million to hedge probable, but not firmly committed, future transactions associated with our debt. In December 2014 , we terminated notional amounts of $875 million of pay-floating interest rate swaps in connection with the debt redemption described in our 2015 10-K. These swaps were previously designated as fair value hedges. As a result of this redemption, we also incurred a loss on the extinguishment of debt of $60 million ( $37 million , net of tax), which included a make-whole premium of $80 million , write-off of $2 million of unamortized debt issuance costs, and an offsetting $22 million fair value adjustment to the respective debt related to previously terminated interest rate swaps. Fair Value of Financial Instruments The carrying amounts of cash and equivalents, trade receivables, net, accounts payable, and other accrued liabilities at December 31, 2015 and June 30, 2015 approximate fair value due to their short-term maturities. The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) December 31, 2015 June 30, Estimated fair value $ 5,625 $ 5,521 Carrying amount 5,525 5,492 The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests Redeemable Noncontrolling Interests	6 Months Ended
	Dec. 31, 2015
Redeemable Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	Redeemable Noncontrolling Interests In connection with the acquisition of a 71 percent ownership interest in naviHealth described in Note 2, we recognized noncontrolling interests with a fair value of $119 million at the acquisition date. The noncontrolling interests are redeemable at the option of the third-party noncontrolling interests holders at any time after the two-year anniversary of the closing. As such, the noncontrolling interests have been presented as redeemable noncontrolling interests in our condensed consolidated balance sheets. The noncontrolling interests will be adjusted each period for net earnings and dividends attributable to the noncontrolling interests and changes in the noncontrolling ownership interests in naviHealth, if any. An additional adjustment to the carrying value of the noncontrolling interests may be required if the redemption value under the terms of the agreement exceeds the carrying value. Changes in the carrying value of the noncontrolling interests related to a change in the redemption value will be recorded through retained earnings and will not affect net earnings attributable to Cardinal Health, Inc. The reconciliation of the changes in redeemable noncontrolling interests are as follows: (in millions) Balance at June 30, 2015 $ — Redeemable noncontrolling interests acquired 119 Net earnings attributable to redeemable noncontrolling interests 1 Balance at December 31, 2015 $ 120

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity During the six months ended December 31, 2015 , we did not repurchase any common shares. During the six months ended December 31, 2014 , we repurchased 9.1 million common shares having an aggregate cost of $684 million . The average price paid per common share was $75.00 . We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes. Accumulated Other Comprehensive Loss The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2015 $ (41 ) $ 18 $ (23 ) Other comprehensive loss, net of tax before reclassifications (73 ) (1 ) (74 ) Amounts reclassified to earnings — — — Total other comprehensive loss (73 ) (1 ) (74 ) Balance at December 31, 2015 $ (114 ) $ 17 $ (97 ) Activity related to realized and unrealized gains and losses on available-for-sale securities, as described in Note 5, was immaterial during the three and six months ended December 31, 2015 .

Earnings Per Share

Earnings Per Share	6 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Attributable to Cardinal Health, Inc. The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.: Three Months Ended December 31 (in millions) 2015 2014 Weighted-average common shares–basic 329 331 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 3 3 Weighted-average common shares–diluted 332 334 Six Months Ended December 31 (in millions) 2015 2014 Weighted-average common shares–basic 329 333 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 3 4 Weighted-average common shares–diluted 332 337 The potentially dilutive employee stock options, restricted share units, and performance share units that were antidilutive were 2 million and 1 million for the three months ended December 31, 2015 and 2014 , respectively, and 2 million and 1 million for the six months ended December 31, 2015 and 2014 , respectively.

Segment Information

Segment Information	6 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Information	Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. The following tables present revenue for each reportable segment and Corporate: Three Months Ended December 31 (in millions) 2015 2014 Pharmaceutical $ 28,287 $ 22,627 Medical 3,162 2,914 Total segment revenue 31,449 25,541 Corporate (1) (4 ) (4 ) Total revenue $ 31,445 $ 25,537 Six Months Ended December 31 (in millions) 2015 2014 Pharmaceutical $ 53,427 $ 43,836 Medical 6,081 5,766 Total segment revenue 59,508 49,602 Corporate (1) (9 ) 5 Total revenue $ 59,499 $ 49,607 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment SG&A expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance. The results attributable to noncontrolling interests are recorded within segment profit. Corporate expenses are allocated to the segments based on headcount, level of benefit provided, and other ratable allocation methodologies. We do not allocate the following items to our segments: LIFO inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; other income, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes. In addition, certain investment spending, certain portions of enterprise-wide incentive compensation, and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. We encourage our segments and corporate functions to identify investment projects that will promote innovation and provide future returns. As approval decisions for such projects are dependent upon executive management, the expenses for such projects are often retained at Corporate. Investment spending within Corporate was $5 million and $4 million for the three months ended December 31, 2015 and 2014 , respectively, and $11 million and $6 million for the six months ended December 31, 2015 and 2014 , respectively. The following tables present segment profit by reportable segment and Corporate: Three Months Ended December 31 (in millions) 2015 2014 Pharmaceutical $ 627 $ 542 Medical 106 115 Total segment profit 733 657 Corporate (170 ) (111 ) Total operating earnings $ 563 $ 546 Six Months Ended December 31 (in millions) 2015 2014 Pharmaceutical $ 1,285 $ 992 Medical 207 229 Total segment profit 1,492 1,221 Corporate (309 ) (209 ) Total operating earnings $ 1,183 $ 1,012 The following table presents total assets for each reportable segment and Corporate at: (in millions) December 31, June 30, Pharmaceutical $ 20,464 $ 17,385 Medical 9,741 7,095 Corporate 3,302 5,662 Total assets $ 33,507 $ 30,142

Share-Based Compensation and Sa

Share-Based Compensation and Savings Plans	6 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation and Savings Plans	Share-Based Compensation Share-Based Compensation Plans We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors, and employees. The following tables provide total share-based compensation expense by type of award: Three Months Ended December 31 (in millions) 2015 2014 Restricted share unit expense $ 17 $ 18 Employee stock option expense 5 5 Performance share unit expense 4 5 Total share-based compensation $ 26 $ 28 Six Months Ended December 31 (in millions) 2015 2014 Restricted share unit expense $ 35 $ 34 Employee stock option expense 10 10 Performance share unit expense 11 9 Total share-based compensation $ 56 $ 53 The total tax benefit related to share-based compensation was $9 million for both the three months ended December 31, 2015 and 2014 , and $19 million and $18 million for the six months ended December 31, 2015 and 2014, respectively. Stock Options Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for periods ranging from seven to ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date. The following table summarizes all stock option transactions under the Plans: (in millions, except per share amounts) Stock Options Weighted-Average Exercise Price per Common Share Outstanding at June 30, 2015 8 $ 46.50 Granted 1 84.19 Exercised (1 ) 40.31 Canceled and forfeited — — Outstanding at December 31, 2015 8 $ 53.45 Exercisable at December 31, 2015 5 $ 42.05 At December 31, 2015 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $32 million , which is expected to be recognized over a weighted-average period of two years . The following table provides additional detail related to stock options: (in millions, except per share amounts) December 31, 2015 June 30, 2015 Aggregate intrinsic value of outstanding options at period end $ 277 $ 281 Aggregate intrinsic value of exercisable options at period end 233 193 Weighted-average remaining contractual life of outstanding options (in years) 7 6 Weighted-average remaining contractual life of exercisable options (in years) 5 5 Restricted Share Units Restricted share units granted under the Plans generally vest in equal annual installments over three years . Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2015 3 $ 59.69 Granted 1 84.22 Vested (1 ) 53.96 Canceled and forfeited — — Nonvested at December 31, 2015 3 $ 70.84 At December 31, 2015 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $109 million , which is expected to be recognized over a weighted-average period of two years . Performance Share Units Performance share units vest over a three -year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 200 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2015 0.9 $ 50.31 Granted 0.3 84.26 Vested (1) (0.4 ) 39.81 Canceled and forfeited — — Nonvested at December 31, 2015 0.8 $ 62.61 (1) Vested based on achievement of 133 percent of the target performance goal. At December 31, 2015 , the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $22 million , which is expected to be recognized over a weighted-average period of two years .

Basis of Presentation and Sum21

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation, Policy	Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December 31, 2015 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the effective date of the acquisition or up to the date of disposal, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include all of the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In addition, operating results presented for this fiscal 2016 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2016 . These condensed consolidated financial statements are unaudited and are presented pursuant to the rules and regulations of the SEC. Accordingly, the condensed consolidated financial statements included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (the "2015 Form 10-K"). In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.
Inventory, Policy [Policy Text Block]	Inventories A substantial portion of our inventories are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within these distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation. Interim LIFO calculations are based on our estimates of expected year-end inventory levels and costs, as the actual valuation of inventory under the LIFO method is computed at the end of the fiscal year based on the inventory levels and costs at that time. Based upon the year-to-date balance and expectations for the remainder of the fiscal year, we recorded a LIFO charge of $39 million for the three months ended December 31, 2015 , which is included in cost of products sold in the condensed consolidated financial statements.
Recent Financial Accounting Standards, Policy	Recent Financial Accounting Standards In January 2016, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance intended to improve the recognition and measurement of financial instruments as part of a larger simplification initiative. The amended guidance primarily changes the accounting for equity method investments, financial liabilities under the fair value option, the method for assessing the realizability of deferred tax assets related to available-for-sale securities, and the presentation and disclosure requirements for financial instruments. This classification and measurement guidance will be effective for us in the first quarter of fiscal 2019, with early adoption permitted. We are currently evaluating the impact of the adoption on our consolidated financial statements. In November 2015, the FASB issued amended accounting guidance that simplifies the accounting for income taxes. Under this amended guidance, deferred tax assets and liabilities must be classified as noncurrent on the balance sheet instead of separating deferred tax items into current and noncurrent amounts. We adopted this guidance on a prospective basis in the second quarter of fiscal 2016. Upon adoption of this guidance, current deferred tax assets of $20 million and current deferred tax liabilities of $1.1 billion in our December 31, 2015 condensed consolidated balance sheet were reclassified as noncurrent. In accordance with the adoption of this guidance, balances were not retrospectively adjusted. The adoption of this guidance had no impact on our condensed consolidated statements of earnings, comprehensive income or cash flows. In September 2015, the FASB issued amended accounting guidance that eliminates the requirement that an acquirer in a business combination account for measurement-period adjustments on a retrospective basis. Under this amended guidance, the acquirer will recognize a measurement-period adjustment during the period in which it determines the amount of the adjustment. We adopted this guidance in the second quarter of fiscal 2016. The adoption of this guidance did not materially impact our condensed consolidated financial statements. In May 2014, the FASB issued amended accounting guidance related to revenue recognition. This guidance is based on the principle that revenue is recognized in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to customers. The guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB deferred the effective date for one year beyond the originally specified effective date. This amendment will be effective for us in the first quarter of fiscal 2019. We are continuing to evaluate the options for adoption and the impact on our consolidated financial statements. In April 2014, the FASB issued amended accounting guidance related to the reporting of discontinued operations and disclosures of disposals of components of an entity. The amended guidance changes the thresholds for disposals to qualify as discontinued operations and requires additional disclosures. We adopted this guidance in the first quarter of fiscal 2016. The adoption of this guidance did not impact our condensed consolidated financial statements.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	(in millions) Cordis naviHealth Harvard Drug Identifiable intangible assets: Customer relationships (1) $ 230 $ 38 $ 470 Trade names (2) 130 16 130 Developed technology (3) 400 61 — In-process research and development (4) 55 — — Total identifiable intangible assets acquired 815 115 600 Cash and equivalents — 53 46 Trade receivables — 38 67 Inventories 213 — 49 Prepaid expenses and other 4 14 12 Property and equipment 98 5 16 Other assets 10 1 1 Accounts payable (81 ) (2 ) (48 ) Other accrued liabilities (11 ) (95 ) (39 ) Deferred income taxes and other liabilities (7 ) (42 ) (104 ) Redeemable noncontrolling interests — (119 ) — Total identifiable net assets/(liabilities) acquired 1,041 (32 ) 600 Goodwill 832 323 551 Total net assets acquired $ 1,873 $ 291 $ 1,151 (1) The weighted-average useful lives of customer relationships range from 4 to 13 years. (2) The weighted-average useful lives of trade names range from 10 to 17 years. (3) The weighted-average useful life of developed technology is 10 years. (4) Acquired in-process research and development ("IPR&D") intangible assets have an indefinite-life.

Restructuring and Employee Se23

Restructuring and Employee Severance (Tables)	6 Months Ended
	Dec. 31, 2015
Restructuring Charges [Abstract]
Summary of Restructuring and Employee Severance	The following tables summarize restructuring and employee severance costs: Three Months Ended December 31 (in millions) 2015 2014 Employee-related costs (1) $ — $ 5 Facility exit and other costs (2) 2 2 Total restructuring and employee severance $ 2 $ 7 Six Months Ended December 31 (in millions) 2015 2014 Employee-related costs (1) $ 6 $ 21 Facility exit and other costs (2) 8 5 Total restructuring and employee severance $ 14 $ 26 (1) Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods. (2) Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees, and costs associated with restructuring our delivery of information technology infrastructure services.
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance	The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Related Costs Facility Exit and Other Costs Total Balance at June 30, 2015 $ 22 $ — $ 22 Additions 7 2 9 Payments and other adjustments (13 ) — (13 ) Balance at December 31, 2015 $ 16 $ 2 $ 18

Goodwill and Other Intangible24

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill by Reportable Segment	The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical Total Balance at June 30, 2015 $ 2,199 $ 2,871 $ 5,070 Goodwill acquired, net of purchase price adjustments 578 1,178 1,756 Foreign currency translation adjustments and other (13 ) (14 ) (27 ) Balance at December 31, 2015 $ 2,764 $ 4,035 $ 6,799
Schedule of Intangible Assets	The following tables summarize other intangible assets by class at: December 31, 2015 (in millions) Gross Intangible Accumulated Amortization Net Intangible Weighted Average Remaining Amortization Period (Years) Indefinite-life intangibles: IPR&D, trademarks and other $ 69 $ — $ 69 N/A Total indefinite-life intangibles 69 — 69 N/A Definite-life intangibles: Customer relationships 1,826 620 1,206 10 Trademarks, trade names, and patents 512 112 400 15 Developed technology and other 793 154 639 10 Total definite-life intangibles 3,131 886 2,245 11 Total other intangible assets $ 3,200 $ 886 $ 2,314 N/A June 30, 2015 (in millions) Gross Intangible Accumulated Amortization Net Intangible Indefinite-life intangibles: Trademarks and other $ 14 $ — $ 14 Total indefinite-life intangibles 14 — 14 Definite-life intangibles: Customer relationships 1,103 501 602 Trademarks, trade names, and patents 237 91 146 Developed technology and other 320 134 186 Total definite-life intangibles 1,660 726 934 Total other intangible assets $ 1,674 $ 726 $ 948

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	6 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	We held the following investments in marketable securities at fair value at: (in millions) December 31, 2015 June 30, 2015 Current available-for-sale securities: Commercial paper $ 2 $ 4 Treasury bills 2 12 International bonds — 2 Corporate bonds 53 34 U.S. agency bonds 1 5 Asset-backed securities 28 8 International equity securities 2 — U.S. agency mortgage-backed securities 16 26 Total current available-for-sale securities 104 91 Long-term available-for-sale securities: International bonds 1 — Corporate bonds 29 33 U.S. agency bonds 31 18 Asset-backed securities 20 41 U.S. agency mortgage-backed securities 13 10 Total long-term available-for-sale securities 94 102 Total available-for-sale securities $ 198 $ 193

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2015
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: December 31, 2015 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents (1) $ 554 $ — $ — $ 554 Forward contracts (2) — 5 — 5 Available-for-sale securities (3) — 198 — 198 Other investments (4) 115 — — 115 Liabilities: Contingent Consideration (5) — — (23 ) (23 ) June 30, 2015 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents (1) $ 1,809 $ — $ — $ 1,809 Forward contracts (2) — 5 — 5 Available-for-sale securities (3) — 193 — 193 Other investments (4) 111 — — 111 Liabilities: Contingent Consideration (5) — — (53 ) (53 ) (1) Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities. (2) The fair value of interest rate swaps, foreign currency contracts, and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets. (3) We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves, and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities. (4) The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (5) Contingent consideration represents the obligations incurred in connection with acquisitions. We do not deem the fair value of the contingent consideration obligations under any single acquisition to be significant. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or from achieving certain milestones. The fair value measurement is based on significant inputs unobservable in the market and thus represents a Level 3 measurement. Failure to meet current expectations of progress could increase the probability of not achieving the targets within the measurement periods and result in a reduction in the fair value of the contingent consideration obligation.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table presents a reconciliation of those liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3): (in millions) Contingent Consideration Obligation Balance at June 30, 2015 $ 53 Additions from acquisitions 7 Changes in fair value of contingent consideration (1) (14 ) Payment of contingent consideration (23 ) Balance at December 31, 2015 $ 23 (1) Amount is included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amounts	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) December 31, 2015 June 30, Estimated fair value $ 5,625 $ 5,521 Carrying amount 5,525 5,492

Redeemable Noncontrolling Int28

Redeemable Noncontrolling Interests (Tables)	6 Months Ended
	Dec. 31, 2015
Redeemable Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest [Table Text Block]	(in millions) Balance at June 30, 2015 $ — Redeemable noncontrolling interests acquired 119 Net earnings attributable to redeemable noncontrolling interests 1 Balance at December 31, 2015 $ 120

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total	The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Currency Translation Adjustments Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Other Comprehensive Loss Balance at June 30, 2015 $ (41 ) $ 18 $ (23 ) Other comprehensive loss, net of tax before reclassifications (73 ) (1 ) (74 ) Amounts reclassified to earnings — — — Total other comprehensive loss (73 ) (1 ) (74 ) Balance at December 31, 2015 $ (114 ) $ 17 $ (97 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share	The following tables reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.: Three Months Ended December 31 (in millions) 2015 2014 Weighted-average common shares–basic 329 331 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 3 3 Weighted-average common shares–diluted 332 334 Six Months Ended December 31 (in millions) 2015 2014 Weighted-average common shares–basic 329 333 Effect of dilutive securities: Employee stock options, restricted share units, and performance share units 3 4 Weighted-average common shares–diluted 332 337

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenue by Reportable Segment	The following tables present revenue for each reportable segment and Corporate: Three Months Ended December 31 (in millions) 2015 2014 Pharmaceutical $ 28,287 $ 22,627 Medical 3,162 2,914 Total segment revenue 31,449 25,541 Corporate (1) (4 ) (4 ) Total revenue $ 31,445 $ 25,537 Six Months Ended December 31 (in millions) 2015 2014 Pharmaceutical $ 53,427 $ 43,836 Medical 6,081 5,766 Total segment revenue 59,508 49,602 Corporate (1) (9 ) 5 Total revenue $ 59,499 $ 49,607 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment	The following tables present segment profit by reportable segment and Corporate: Three Months Ended December 31 (in millions) 2015 2014 Pharmaceutical $ 627 $ 542 Medical 106 115 Total segment profit 733 657 Corporate (170 ) (111 ) Total operating earnings $ 563 $ 546 Six Months Ended December 31 (in millions) 2015 2014 Pharmaceutical $ 1,285 $ 992 Medical 207 229 Total segment profit 1,492 1,221 Corporate (309 ) (209 ) Total operating earnings $ 1,183 $ 1,012
Assets by Reportable Segment	The following table presents total assets for each reportable segment and Corporate at: (in millions) December 31, June 30, Pharmaceutical $ 20,464 $ 17,385 Medical 9,741 7,095 Corporate 3,302 5,662 Total assets $ 33,507 $ 30,142

Share-Based Compensation and 32

Share-Based Compensation and Savings Plans (Tables)	6 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Total Share-based Compensation Expense by Type of Award	The following tables provide total share-based compensation expense by type of award: Three Months Ended December 31 (in millions) 2015 2014 Restricted share unit expense $ 17 $ 18 Employee stock option expense 5 5 Performance share unit expense 4 5 Total share-based compensation $ 26 $ 28 Six Months Ended December 31 (in millions) 2015 2014 Restricted share unit expense $ 35 $ 34 Employee stock option expense 10 10 Performance share unit expense 11 9 Total share-based compensation $ 56 $ 53
Schedule of Stock Option Transactions Under the Plans	The following table summarizes all stock option transactions under the Plans: (in millions, except per share amounts) Stock Options Weighted-Average Exercise Price per Common Share Outstanding at June 30, 2015 8 $ 46.50 Granted 1 84.19 Exercised (1 ) 40.31 Canceled and forfeited — — Outstanding at December 31, 2015 8 $ 53.45 Exercisable at December 31, 2015 5 $ 42.05
Schedule of Additional Data Related to Stock Option Activity	The following table provides additional detail related to stock options: (in millions, except per share amounts) December 31, 2015 June 30, 2015 Aggregate intrinsic value of outstanding options at period end $ 277 $ 281 Aggregate intrinsic value of exercisable options at period end 233 193 Weighted-average remaining contractual life of outstanding options (in years) 7 6 Weighted-average remaining contractual life of exercisable options (in years) 5 5
Schedule of Transactions Related to Restricted Share Units Under the Plans	The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2015 3 $ 59.69 Granted 1 84.22 Vested (1 ) 53.96 Canceled and forfeited — — Nonvested at December 31, 2015 3 $ 70.84
Schedule of Transactions Related to Performance Share Units Under the Plans	The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Share Units Weighted-Average Grant Date Fair Value per Share Nonvested at June 30, 2015 0.9 $ 50.31 Granted 0.3 84.26 Vested (1) (0.4 ) 39.81 Canceled and forfeited — — Nonvested at December 31, 2015 0.8 $ 62.61 (1) Vested based on achievement of 133 percent of the target performance goal.

Basis of Presentation and Sum33

Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions	3 Months Ended
	Dec. 31, 2015USD ($)
Accounting Policies [Abstract]
Inventory, LIFO Reserve, Period Charge	$ 39
Deferred Tax Assets, Net, Current	20
Deferred Tax Liabilities, Net, Current	$ 1,100

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Millions	Oct. 02, 2015USD ($)country	Aug. 26, 2015USD ($)	Jul. 02, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Business Acquisition
Cash paid for acquisitions, net of cash acquired					$ 3,284	$ 86
Fair Value, Inputs, Level 3 | Minimum
Business Acquisition
Fair Value Inputs, Discount Rate					12.00%
Fair Value, Inputs, Level 3 | Maximum
Business Acquisition
Fair Value Inputs, Discount Rate					14.00%
naviHealth
Business Acquisition
Cash paid for acquisitions, net of cash acquired		$ 238
Noncontrolling Interest, Ownership Percentage by Parent		71.00%
Cash Acquired from Acquisition		$ 53
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		29.00%
Harvard Drug Group
Business Acquisition
Cash paid for acquisitions, net of cash acquired			$ 1,100
Cordis
Business Acquisition
Cash paid for acquisitions, net of cash acquired	$ 1,900
Number of countries in which the entity operates | country	50
Transaction and integration costs				$ 20	$ 41
Customer relationships | Minimum
Business Acquisition
Weighted-Average Useful Life					4 years
Customer relationships | Maximum
Business Acquisition
Weighted-Average Useful Life					13 years
Trade Names [Member] | Minimum
Business Acquisition
Weighted-Average Useful Life					10 years
Trade Names [Member] | Maximum
Business Acquisition
Weighted-Average Useful Life					17 years
Developed technology and other | naviHealth
Business Acquisition
Weighted-Average Useful Life					10 years

Acquisitions Schedule of Estima

Acquisitions Schedule of Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions		Dec. 31, 2015	Aug. 26, 2015	Jun. 30, 2015
Business Acquisition [Line Items]
Redeemable Noncontrolling Interests			$ (119)
Goodwill		$ 6,799		$ 5,070
naviHealth [Member]
Business Acquisition [Line Items]
Identifiable intangible asset		115
Cash and Equivalents		53
Trade Receivables		38
Inventories		0
Prepaid Expense and Other		14
Property and Equipment		5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets		1
Accounts Payable		(2)
Other accrued liabilities		(95)
Deferred Income Tax Liabilities and Other Liabilities		(42)
Redeemable Noncontrolling Interests		(119)
Total identifiable net assets/(liabilities) acquired		(32)
Goodwill		323
Total net assets acquired		291
Harvard Drug Group [Member]
Business Acquisition [Line Items]
Identifiable intangible asset		600
Cash and Equivalents		46
Trade Receivables		67
Inventories		49
Prepaid Expense and Other		12
Property and Equipment		16
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets		1
Accounts Payable		(48)
Other accrued liabilities		(39)
Deferred Income Tax Liabilities and Other Liabilities		(104)
Redeemable Noncontrolling Interests		0
Total identifiable net assets/(liabilities) acquired		600
Goodwill		551
Total net assets acquired		1,151
Cordis [Member]
Business Acquisition [Line Items]
Identifiable intangible asset		815
Cash and Equivalents		0
Trade Receivables		0
Inventories		213
Prepaid Expense and Other		4
Property and Equipment		98
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets		10
Accounts Payable		(81)
Other accrued liabilities		(11)
Deferred Income Tax Liabilities and Other Liabilities		(7)
Redeemable Noncontrolling Interests		0
Total identifiable net assets/(liabilities) acquired		1,041
Goodwill		832
Total net assets acquired		1,873
Customer relationships | naviHealth [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[1]	38
Customer relationships | Harvard Drug Group [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[1]	470
Customer relationships | Cordis [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[1]	230
Trade Names | naviHealth [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[2]	16
Trade Names | Harvard Drug Group [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[2]	130
Trade Names | Cordis [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[2]	130
Developed technology and other | naviHealth [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[3]	61
Developed technology and other | Harvard Drug Group [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[3]	0
Developed technology and other | Cordis [Member]
Business Acquisition [Line Items]
Identifiable intangible asset	[3]	400
In Process Research and Development [Member] | naviHealth [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	[4]	0
In Process Research and Development [Member] | Harvard Drug Group [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	[4]	0
In Process Research and Development [Member] | Cordis [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	[4]	$ 55
[1]	(1)The weighted-average useful lives of customer relationships range from 4 to 13 years.
[2]	(2)The weighted-average useful lives of trade names range from 10 to 17 years.
[3]	(3)The weighted-average useful life of developed technology is 10 years.
[4]	(4)Acquired in-process research and development ("IPR&D") intangible assets have an indefinite-life.

Restructuring and Employee Se36

Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Employee-related costs	[1]	$ 0	$ 5	$ 6	$ 21
Facility exit and other costs	[2]	2	2	8	5
Total restructuring and employee severance		$ 2	$ 7	$ 14	$ 26
[1]	Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated and duplicate payroll costs during transition periods.
[2]	Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees, and costs associated with restructuring our delivery of information technology infrastructure services.

Restructuring and Employee Se37

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) $ in Millions	6 Months Ended
	Dec. 31, 2015USD ($)
Employee-Related Costs
Restructuring Reserve
Beginning Balance	$ 22
Additions	7
Payments and other adjustments	(13)
Ending Balance	16
Facility Exit and Other Costs
Restructuring Reserve
Beginning Balance	0
Additions	2
Payments and other adjustments	0
Ending Balance	2
Total
Restructuring Reserve
Beginning Balance	22
Additions	9
Payments and other adjustments	(13)
Ending Balance	$ 18

Goodwill and Other Intangible38

Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 101	$ 47	$ 168	$ 92
Estimated annual amortization of intangible assets - 2016	189		189
Estimated annual amortization of intangible assets - 2017	368		368
Estimated annual amortization of intangible assets - 2018	308		308
Estimated annual amortization of intangible assets - 2019	255		255
Estimated annual amortization of intangible assets - 2020	$ 228		$ 228

Goodwill and Other Intangible39

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) $ in Millions	6 Months Ended
	Dec. 31, 2015USD ($)
Goodwill
Beginning balance	$ 5,070
Goodwill acquired, net of purchase price adjustments	1,756
Foreign currency translation adjustments and other	(27)
Ending balance	6,799
Pharmaceutical
Goodwill
Beginning balance	2,199
Goodwill acquired, net of purchase price adjustments	578
Foreign currency translation adjustments and other	(13)
Ending balance	2,764
Medical
Goodwill
Beginning balance	2,871
Goodwill acquired, net of purchase price adjustments	1,178
Foreign currency translation adjustments and other	(14)
Ending balance	$ 4,035

Goodwill and Other Intangible40

Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2015	Jun. 30, 2015
Indefinite-life intangibles:
Indefinite-lived intangible assets, gross (excluding goodwill)	$ 69	$ 14
Indefinite-lived intangible assets, accumulated amortization	0	0
Indefinite-lived intangible assets, net (excluding goodwill)	69	14
Definite-life intangibles:
Finite-lived intangible assets, gross	3,131	1,660
Finite-lived intangible assets, accumulated amortization	886	726
Finite-lived intangible assets, net	$ 2,245	934
Weighted average remaining amortization period (years)	11 years
Intangible assets, gross (excluding goodwill)	$ 3,200	1,674
Intangible assets, net (excluding goodwill)	2,314	948
Customer relationships
Definite-life intangibles:
Finite-lived intangible assets, gross	1,826	1,103
Finite-lived intangible assets, accumulated amortization	620	501
Finite-lived intangible assets, net	$ 1,206	602
Weighted average remaining amortization period (years)	10 years
Trademarks, trade names, and patents
Definite-life intangibles:
Finite-lived intangible assets, gross	$ 512	237
Finite-lived intangible assets, accumulated amortization	112	91
Finite-lived intangible assets, net	$ 400	146
Weighted average remaining amortization period (years)	15 years
Developed technology and other
Definite-life intangibles:
Finite-lived intangible assets, gross	$ 793	320
Finite-lived intangible assets, accumulated amortization	154	134
Finite-lived intangible assets, net	$ 639	186
Weighted average remaining amortization period (years)	10 years
IPR&D, trademarks and other
Indefinite-life intangibles:
Indefinite-lived intangible assets, gross (excluding goodwill)	$ 69	14
Indefinite-lived intangible assets, accumulated amortization	0	0
Indefinite-lived intangible assets, net (excluding goodwill)	$ 69	$ 14

Available-for-Sale Securities41

Available-for-Sale Securities (Narrative) (Details)	6 Months Ended
	Dec. 31, 2015
Short Term
Schedule of Available-for-sale Securities [Line Items]
Weighted average effective maturity	6 months
Long Term
Schedule of Available-for-sale Securities [Line Items]
Weighted average effective maturity	14 months

Available-for-Sale Securities42

Available-for-Sale Securities (Schedule of Available-for-Sale Securities) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	$ 104	$ 91
Available-for-sale securities, long-term	94	102
Available-for-sale securities	198	193
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	2	4
Treasury bills
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	2	12
International bonds
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	0	2
Available-for-sale securities, long-term	1	0
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	53	34
Available-for-sale securities, long-term	29	33
U.S. agency bonds
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	1	5
Available-for-sale securities, long-term	31	18
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	28	8
Available-for-sale securities, long-term	20	41
Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	2	0
U.S. agency mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, current	16	26
Available-for-sale securities, long-term	$ 13	$ 10

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015
Income Taxes
Effective Income Tax Rate Reconciliation, Percent	37.30%	36.00%	34.70%	37.40%
Net unfavorable/(favorable) discrete items, amount			$ 28,000,000
Unrecognized tax benefits	$ 530,000,000		530,000,000		$ 542,000,000
Unrecognized tax benefits that would impact effective tax rate	348,000,000		348,000,000		357,000,000
Unrecognized tax benefits, interest and penalties accrued	154,000,000		154,000,000		169,000,000
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority	222,000,000		222,000,000		$ 219,000,000
Minimum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months	0		0
Maximum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months	$ 190,000,000		$ 190,000,000
Federal | Minimum
Income Taxes
Tax years open for examination	2,006
Federal | Maximum
Income Taxes
Tax years open for examination	2,015
State | Minimum
Income Taxes
Tax years open for examination	2,006
State | Maximum
Income Taxes
Tax years open for examination	2,015
Foreign | Minimum
Income Taxes
Tax years open for examination	2,006
Foreign | Maximum
Income Taxes
Tax years open for examination	2,015

Commitments, Contingent Liabi44

Commitments, Contingent Liabilities and Litigation (Narrative) (Details) $ in Millions	3 Months Ended	6 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Jun. 30, 2015USD ($)
Loss Contingencies
Proceeds from Legal Settlements	$ 13	$ 13
Commitments [Abstract]
Payments to Acquire Businesses, Net of Cash Acquired		3,284	$ 86
DEA Investigation and Related Matters
Loss Contingencies
Litigation accrual	$ 44	$ 44		$ 41
CVS Health
Commitments [Abstract]
Initial term of Pharmaceutical Sourcing Venture		10 years
Number of quarterly payments		39
Quarterly payment		$ 25.6
Increase in quarterly payments		10
Fiscal 2017 | CVS Health
Commitments [Abstract]
Further Increase in Quarterly Payments		10
Maximum Quarterly Payment		$ 45.6

Fair Value Measurements (Fair V

Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($) $ in Millions		Dec. 31, 2015	Jun. 30, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Available-for-sale securities		$ 198	$ 193
Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash equivalents	[1]	554	1,809
Forward contracts	[2]	5	5
Available-for-sale securities	[3]	198	193
Other investments	[4]	115	111
Contingent Consideration	[5]	(23)	(53)
Recurring | Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash equivalents	[1]	554	1,809
Forward contracts	[2]	0	0
Available-for-sale securities	[3]	0	0
Other investments	[4]	115	111
Contingent Consideration	[5]	0	0
Recurring | Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash equivalents	[1]	0	0
Forward contracts	[2]	5	5
Available-for-sale securities	[3]	198	193
Other investments	[4]	0	0
Contingent Consideration	[5]	0	0
Recurring | Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Cash equivalents	[1]	0	0
Forward contracts	[2]	0	0
Available-for-sale securities	[3]	0	0
Other investments	[4]	0	0
Contingent Consideration	[5]	$ (23)	$ (53)
[1]	Cash equivalents are comprised of highly liquid investments purchased with a maturity of three months or less. The carrying value of these cash equivalents approximates fair value due to their short-term maturities.
[2]	The fair value of interest rate swaps, foreign currency contracts, and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in the condensed consolidated balance sheets.
[3]	We invest in marketable securities, which are classified as available-for-sale and are carried at fair value in the condensed consolidated balance sheets. Observable Level 2 inputs such as quoted prices for similar securities, interest rate spreads, yield curves, and credit risk are used to determine the fair value. See Note 5 for additional information regarding available-for-sale securities.
[4]	The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds primarily invest in the equity securities of companies with large market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
[5]	Contingent consideration represents the obligations incurred in connection with acquisitions. We do not deem the fair value of the contingent consideration obligations under any single acquisition to be significant. The estimate of fair value of the contingent consideration obligations requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of reaching various targets or from achieving certain milestones. The fair value measurement is based on significant inputs unobservable in the market and thus represents a Level 3 measurement. Failure to meet current expectations of progress could increase the probability of not achieving the targets within the measurement periods and result in a reduction in the fair value of the contingent consideration obligation.

Fair Value Measurements Reconci

Fair Value Measurements Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3) (Details) - Recurring - Contingent Consideration $ in Millions	6 Months Ended
	Dec. 31, 2015USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 53
Additions from acquisitions	7
Changes in fair value of contingent consideration	(14)	[1]
Payment of contingent consideration	(23)
Balance at end of period	$ 23
[1]	Amount is included in amortization and other acquisition-related costs in the condensed consolidated statements of earnings.

Redeemable Noncontrolling Int47

Redeemable Noncontrolling Interests (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Aug. 26, 2015
Redeemable Noncontrolling Interest [Line Items]
Redeemable Noncontrolling Interest, Equity, Fair Value		$ 119
naviHealth [Member]
Redeemable Noncontrolling Interest [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		71.00%
Redeemable Noncontrolling Interest, Equity, Fair Value	$ 119

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2014
Derivative [Line Items]
Loss on Extinguishment of Debt	$ 0	$ 60	$ 0	$ 60
Extinguishment of Debt, Gain (Loss), Net of Tax		37
Payments of Debt Extinguishment Costs		80
Write off of Deferred Debt Issuance Cost		2
Fair value adjustment due to termination of interest rate swap		22
Designated as Hedging Instrument | Fair Value Hedging [Member] | Interest Rate Swaps
Derivative [Line Items]
Derivative, notional amount	$ 300	450	$ 300	450
Forward Contracts | Designated as Hedging Instrument | Cash Flow Hedging | Interest Rate Swaps
Derivative [Line Items]
Derivative, notional amount					$ 50
Deb Redemption [Member] | Designated as Hedging Instrument | Fair Value Hedging [Member] | Interest Rate Swaps
Derivative [Line Items]
Derivative, notional amount		$ 875		$ 875

Financial Instruments (Summary

Financial Instruments (Summary of estimated fair value of our long-term obligations and other short-term borrowings) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying amount	$ 5,525	$ 5,492
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	$ 5,625	$ 5,521

Redeemable Noncontrolling Int50

Redeemable Noncontrolling Interests (Details) $ in Millions	6 Months Ended
	Dec. 31, 2015USD ($)
Noncontrolling Interest [Line Items]
Balance at June 30, 2015	$ 0
Redeemable noncontrolling interests acquired	119
Net earnings attributable to redeemable noncontrolling interests	1
Balance at September 30, 2015	$ 120

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - Treasury Shares $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended
	Dec. 31, 2014USD ($)$ / sharesshares
Treasury shares acquired (using cost method), shares | shares	9.1
Treasury shares acquired (using cost method), value | $	$ 684
Treasury shares acquired, average price per share (in dollars per share) | $ / shares	$ 75

Shareholders' Equity (Schedule

Shareholders' Equity (Schedule of the changes in the balance in accumulated other comprehensive loss by component and in total) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive loss at beginning of period			$ (23)
Other comprehensive loss, net of tax before reclassifications			(74)
Amounts reclassified to earnings			0
Other comprehensive loss, unrealized gain/(loss) on derivatives, net of tax	$ (1)	$ (9)	(1)	$ (9)
Total other comprehensive loss, net of tax			(74)
Accumulated other comprehensive loss at end of period	(97)		(97)
Foreign Currency Translation Adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive loss at beginning of period			(41)
Other comprehensive loss, net of tax before reclassifications			(73)
Amounts reclassified to earnings			0
Other comprehensive loss, foreign currency translation adjustments net of tax			(73)
Accumulated other comprehensive loss at end of period	(114)		(114)
Unrealized Gain/(Loss) on Derivatives, net of tax
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive loss at beginning of period			18
Other comprehensive loss, net of tax before reclassifications			(1)
Amounts reclassified to earnings			0
Other comprehensive loss, unrealized gain/(loss) on derivatives, net of tax			(1)
Accumulated other comprehensive loss at end of period	$ 17		$ 17

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Potentially dilutive employee stock options, restricted share units and performance share units that were anitdilutive	2	1	2	1

Earnings Per Share (Reconciliat

Earnings Per Share (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Weighted-average common shares–basic (in shares)	329	331	329	333
Effect of dilutive securities:
Employee stock options, restricted share units and performance share units	3	3	3	4
Weighted-average common shares–diluted (in shares)	332	334	332	337

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)SegmentsReportable_Segments	Dec. 31, 2014USD ($)	Jun. 30, 2015SegmentsReportable_Segments
Segment Reporting [Abstract]
Number of operating segments | Segments			2		2
Number of reportable segments | Reportable_Segments			2		2
Project costs on investment and other spending | $	$ 5	$ 4	$ 11	$ 6

Segment Information (Revenue by

Segment Information (Revenue by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenue	$ 31,445	$ 25,537	$ 59,499	$ 49,607
Pharmaceutical
Segment Reporting Information [Line Items]
Revenue	28,287	22,627	53,427	43,836
Medical
Segment Reporting Information [Line Items]
Revenue	3,162	2,914	6,081	5,766
Reportable Segments
Segment Reporting Information [Line Items]
Revenue	31,449	25,541	59,508	49,602
Corporate
Segment Reporting Information [Line Items]
Revenue	$ (4)	$ (4)	$ (9)	$ 5

Segment Information (Segment Pr

Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating earnings	$ 563	$ 546	$ 1,183	$ 1,012
Pharmaceutical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating earnings	627	542	1,285	992
Medical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating earnings	106	115	207	229
Reportable Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating earnings	733	657	1,492	1,221
Corporate
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating earnings	$ (170)	$ (111)	$ (309)	$ (209)

Segment Information (Assets by

Segment Information (Assets by Reportable Segment) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Segment Reporting Information [Line Items]
Assets	$ 33,507	$ 30,142
Pharmaceutical
Segment Reporting Information [Line Items]
Assets	20,464	17,385
Medical
Segment Reporting Information [Line Items]
Assets	9,741	7,095
Corporate
Segment Reporting Information [Line Items]
Assets	$ 3,302	$ 5,662

Share-Based Compensation and 59

Share-Based Compensation and Savings Plans (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit related to share-based compensation	$ 9	$ 9	$ 19	$ 18
Performance Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	22		$ 22
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years
Target performance goal (as a percent)			133.00%
Performance Share Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)			0.00%
Performance Share Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)			200.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	32		$ 32
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years
Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable period of plans (in years)			7 years
Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable period of plans (in years)			10 years
Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			3 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 109		$ 109
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years

Share-Based Compensation and 60

Share-Based Compensation and Savings Plans (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Share-based compensation expense	$ 26	$ 28	$ 56	$ 53
Restricted Share Units
Share-based compensation expense	17	18	35	34
Stock Options
Share-based compensation expense	5	5	10	10
Performance Share Units
Share-based compensation expense	$ 4	$ 5	$ 11	$ 9

Share-Based Compensation and 61

Share-Based Compensation and Savings Plans (Schedule of All Stock Option Transactions Under the Plans) (Details) shares in Millions	6 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Stock Options Outstanding at Beginning of Period | shares	8
Stock Options Outstanding, Granted | shares	1
Stock Options Outstanding, Exercised | shares	(1)
Stock Options Outstanding, Canceled and forfeited | shares	0
Stock Options Outstanding at End of Period | shares	8
Stock Options Outstanding, Exercisable at End of Period | shares	5
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted-Average Exercise Price [Roll Forward]
Weighted-Average Exercise Price Per Common Share, Outstanding at Beginning of Period | $ / shares	$ 46.50
Weighted-Average Exercise Price Per Common Share, Granted | $ / shares	84.19
Weighted-Average Exercise Price Per Common Share, Exercised | $ / shares	40.31
Weighted-Average Exercise Price Per Common Share, Canceled and forfeited | $ / shares	0
Weighted-Average Exercise Price Per Common Share, Outstanding at End of Period | $ / shares	53.45
Weighted-Average Exercise Price Per Common Share, Exercisable at End of Period | $ / shares	$ 42.05

Share-Based Compensation and 62

Share-Based Compensation and Savings Plans (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015
Aggregate intrinsic value of outstanding options at period end	$ 277	$ 281
Aggregate intrinsic value of exercisable options at period end	$ 233	$ 193
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years	6 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years	5 years

Share-Based Compensation and 63

Share-Based Compensation and Savings Plans (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units shares in Millions	6 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested at Beginning of Period | shares	3
Granted | shares	1
Vested | shares	(1)
Canceled and forfeited | shares	0
Nonvested at End of Period | shares	3
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Grant Date Fair Value [Roll Forward]
Weighted-Average Grant Date Fair Value Per Share, Nonvested at Beginning of Period | $ / shares	$ 59.69
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares	84.22
Weighted-Average Grant Date Fair Value Per Share, Vested | $ / shares	53.96
Weighted-Average Grant Date Fair Value Per Share, Canceled and forfeited | $ / shares	0
Weighted-Average Grant Date Fair Value Per Share, Nonvested at End of Period | $ / shares	$ 70.84

Share-Based Compensation and 64

Share-Based Compensation and Savings Plans (Schedule of all Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units shares in Millions	6 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested at Beginning of Period | shares	0.9
Granted | shares	0.3
Vested | shares	(0.4)	[1]
Canceled and forfeited | shares	0
Nonvested at End of Period | shares	0.8
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted-Average Grant Date Fair Value [Roll Forward]
Weighted-Average Grant Date Fair Value Per Share, Nonvested at Beginning of Period | $ / shares	$ 50.31
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares	84.26
Weighted-Average Grant Date Fair Value Per Share, Vested | $ / shares	39.81
Weighted-Average Grant Date Fair Value Per Share, Canceled and forfeited | $ / shares	0
Weighted-Average Grant Date Fair Value Per Share, Nonvested at End of Period | $ / shares	$ 62.61
[1]	Vested based on achievement of 133 percent of the target performance goal.